Cargando…
The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
There is a plethora of published cancer biomarkers but the reality is that very few, if any, new circulating cancer biomarkers have entered the clinic in the last 30 years. I here try to explain this apparent oxymoron by classifying circulating cancer biomarkers into three categories: fraudulent rep...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425158/ https://www.ncbi.nlm.nih.gov/pubmed/22876833 http://dx.doi.org/10.1186/1741-7015-10-87 |